Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.
Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
MiroBio is Harnessing the natural control mechanisms of the immune system.
Ancora Biotech is a privately held company supporting the clinical development of three multi-specific antibodies.
River 2 Renal is a developer of novel therapies intended to cure orphan diseases.
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.
Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.
Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.
Tranquis Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative and aging-related diseases.
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Gladius Pharmaceuticals is a biotechnology firm developing novel drugs to treat life-threatening
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery.
ZappRx is a digital health company that is modernizing and simplifying the way specialty drugs are ordered
Atopix Therapeutics Limited is a privately held, clinical-stage, biopharmaceutical company based in Oxford, UK
Puridify conducts research and development activities on bioprocessing technologies aimed at advancing industrial biomolecule manufacture.
SR One has invested in 65 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
SR One's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Medical. The firm invests across 16 different industry categories.
Among tracked funding rounds, Turning Point Therapeutics received $460.0M in a Post Ipo Equity round. SR One's total known invested capital is $4.4B.
SR One's average investment size is $105.1M across its portfolio of 65 companies.
Recent SR One portfolio additions include Arcellx, Morphic Therapeutic, Pulmocide, Spero Therapeutics, MiroBio. These companies were founded in 2020 or later.